This webinar aims to explore the transformation of safety teams from reactive cost centers to proactive benefit drivers, emphasizing the importance of providing teams with the right tools & resources to gain actionable insights.
向最优秀的人学习
Join us as our expert speakers share valuable insights and practical knowledge drawn from extensive industry experience.
Country Manager Spain & Head of Global Vigilance Division
Dr. Angel Navarro is the Country Manager of Spain of QbD Group and Head of Vigilance Division. Founder and CEO of Azierta for more than 12 years (Azierta part of QbD Group), his track record endorses him as a strategic leader in the international pharmaceutical sector.
Head Global Business Development Pharma
Dr. Antonio Borregón is the Global Business Development Pharma Head at QbD Group. He has extensive experience in the pharmaceutical field with high-responsibility positions at the international level.
Richard Habis, a PharmD graduate from Saint Joseph University of Beirut, is a **seasoned expert in biopharmaceutical consulting and market research.** With a keen focus on rare diseases and patient-centered care, his expertise extends to leveraging real-world data to drive patient outcomes and healthcare insights. Mr. Habis’s professional journey reflects a strong commitment to integrating patient perspectives in digital health solutions.
继续观看
即将举办的网络研讨会As pharmaceutical organizations grow and evolve, Lifecycle Management becomes increasingly difficult to control. This webinar explores how complexity develops across Regulatory Affairs and Pharmacovigilance, and how to structure activities in a more scalable and cost-efficient way.
立即注册
点播网络研讨会This webinar provides guidance on managing pharmacovigilance (PV) across Europe, focusing on balancing global consistency with country-specific requirements. Participants will learn to meet strict European timelines while working with lean teams and practical strategies to enhance oversight and execution.
立即观看
点播网络研讨会The webinar discusses the evolving pharmacovigilance and risk management environment of innovative therapies, emphasizing safety challenges in cell, CAR T, and RNA-based treatments, as well as gaps in regulation and surveillance strategies. Participants will gain insight into the origin and impact of safety concerns in these therapies, alongside ongoing developments in RNA-based treatments.
立即观看